CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($)	1 Months Ended		3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Jun. 30, 2016	Jun. 30, 2015
Cash Flows from Operating Activities
Net loss	$ (33,954)	$ (23,281)	$ (110,112)	$ (66,424)
Adjustment to reconcile net loss to net cash used in operating activities:
Amortization of drug license	0	2,292	0	6,875
Stock-based compensation	0	0	0	0
Changes in operating assets and liabilities:
Increase (decrease) in prepaid expenses	0	(961)	0	836
Increase (decrease) in accounts payable and accrued expenses	3,574	2,806	17,781	15,472
Net cash used in operating activities	(30,380)	(19,144)	(92,331)	(43,241)
Cash Flows from Financing Activities
Proceeds from issuance of common stock	0	0	0	180,000
Proceeds from officer loans	0	10,283	150,310	25,707
Repayments of officer loans	0	0	0	0
Net cash received from financing activities	0	10,283	150,310	205,707
Net increase in cash and cash equivalents	(30,380)	(8,861)	57,979	162,466
Cash and Cash Equivalents, beginning of period	116,642	48,286	86,262	39,425
Cash and Cash Equivalents, end of period	86,262	39,425	144,241	201,891
Supplemental disclosures of cash flow information:
Interest paid	0	0	0	0
Income taxes paid	0	0	0	0
NONCASH INVESTING AND FINANCING ACTIVITIES
Expenses paid by related party	$ 3,278	$ 2,806	$ 9,651	$ 17,398